$JAZZ

AI Analysis

Generated on May 11, 2026

AI Score
68/ 100
Hold$JAZZ

Jazz Pharmaceuticals

$JAZZNASDAQHealthcareLarge-Cap

Jazz develops and commercializes medicines for neuroscience and oncology including Xywav for narcolepsy.

Market Cap
$8.0B
Revenue (TTM)
$3.8B
+5.0%
Net Income (TTM)
$0.5B
+8.0%
EPS (TTM)
$7.50
P/E Ratio
16.0
Dividend Yield
0.0%
52-Week Range
$100-$175
Beta
0.62
Dimension Scores
Fundamental
70
Technical
62
Sentiment
66
Risk / Reward
72
Momentum
60
FundTechSentRiskMome
Financial Health
Profitability
75moderate
Growth
63moderate
Liquidity
80strong
Solvency
72strong
Efficiency
68strong

Valuation, technical analysis, investment thesis, risk assessment and more for $JAZZ

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.